C

CMPX

CMPX

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
53%Neutral
Buy/Sell Ratio2% buys
BearishBullish
CMPX Live QuoteReal-time
$0.61
$0.22(-26.39%)1M
Day Range$0.59 – $0.64
Open$0.62
Previous Close$0.61
Volume1.79M
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$109.26M
P/E Ratio (TTM)24.5
Forward P/ENaN
EPS (TTM)$-0.46
Price to Book0.8
Dividend Yield0.65%
Beta (Volatility)1.06
IndustryBIOTECHNOLOGY
52-Week RangeCurrent: $0.61 (1%)
Low: $0.57High: $6.88
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$5.26-96.5% upside

Insider Buys

8

$183K

Insider Sales

2

$11.36M

Total Volume

$11.54M

15 transactions

Net Activity

$11.17M

Net selling

Proprietary Ratings
Calculated from Form 4 transactions
60CONFIDENCE

Sentiment Rating

Moderate Accumulation

CEO Conviction Index

High Conviction Accumulation

Key Drivers

  • •Heavy distribution: sales represent 98% of total transaction value.
  • •Cluster buying: 3 unique insiders purchased shares, showing strong alignment.
  • •CEO buying activity detected. When chief executives put their own money at risk, it is historically a strong bullish signal.
  • •Significant liquidation: total sale value exceeds $10M.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
M
1

Multiple Insiders

P - Purchase Insiders

0 buys5 sells

$72.19B total

G
2

Gordon Carl L

Dir, 10%

0 buys1 sells

$5.68M total

O
3

Orbimed Advisors LLC

Dir, 10%

0 buys1 sells

$5.68M total

L
4

Lerner Neil

CHIEF ACCOUNTING OFFICER

5 buys0 sells

$84K total

A
5

Anderman Jonathan

GC

2 buys0 sells

$78K total

Trading History
CMPX insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Nov 17, 2026

2 days ago

Lerner Neil

CHIEF ACCOUNTING OFFICER

C-Level
Buy10.0K$0.59$6K

Oct 1, 2026

1 months ago

Lerner Neil

CHIEF ACCOUNTING OFFICER

C-Level
Buy20.0K$0.92$18K

Sep 24, 2026

1 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell400.0K$2500.00$1.00B

Sep 24, 2026

1 months ago

Lerner Neil

CHIEF ACCOUNTING OFFICER

C-Level
Buy2.5K$1.14$3K

Apr 29, 2026

6 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell397.5K$15000.00$5.96B

Apr 29, 2026

6 months ago

Lerner Neil

CHIEF ACCOUNTING OFFICER

C-Level
Buy15.0K$1.89$28K

Apr 29, 2026

6 months ago

Anderman Jonathan

GC

General Counsel
Buy25.0K$1.89$47K

May 27, 2025

18 months ago

Schuetz Thomas J.

CEO

CEO
Buy10.0K$2.11$21K

May 27, 2025

18 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell6.48M$10000.00$64.81B

Apr 9, 2025

19 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell15.22M$-3571428.00$0

Apr 9, 2025

19 months ago

Gordon Carl L

Dir, 10%

Director
Sell3.57M$1.59$5.68M

Apr 9, 2025

19 months ago

Orbimed Advisors LLC

Dir, 10%

Director
Sell3.57M$1.59$5.68M

Apr 7, 2025

19 months ago

Anderman Jonathan

GC, Corporate Sec

General Counsel
Buy20.0K$1.54$31K

Apr 7, 2025

19 months ago

Lerner Neil

CHIEF ACCOUNTING OFFICER

C-Level
Buy20.0K$1.42$28K

Apr 7, 2025

19 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell21.0K$20000.00$420.00M
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
CMPX Buy Conviction2%
Industry Rank#549 of 570
Volume Contribution0.1%
Total Industry Activity$16.44B

CMPX has an insider buy conviction of 2%, compared to the Unknown sector buy average of 6%. CMPX ranks #549 in insider activity out of 570 tracked companies in its industry.

Insider Trading Summary & Commentary
Automated executive transaction analysis for CMPX

Over the last 90 days, corporate insiders at CMPX (CMPX) engaged in a total of 15 transactions reported via SEC Form 4 filings. Among these, 8 were open-market purchases and 2 were sales. The total volume of insider trading reached $11.54M.

The net insider activity for CMPX shows a net selling bias of $11.17M. This activity represents a 2% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 6.48M shares valued at $64.81B on May 27, 2025.

Live Market News & Developments
Aggregated real-time headlines for CMPX (CMPX)
6 updates

Compass Therapeutics Stock Price Forecast. Should You Buy CMPX?

StockInvest.us3d ago

CMPX Stock Crashes To Over 2-Year Lows — Why FDA Wants Another Cancer Therapy Trial Before Key Marketing Filing

Yahoo Finance58d ago

Why Did Compass Therapeutics Stock Plunge Today? - Compass Therapeutics (NASDAQ:CMPX)

Benzinga58d ago

CMPX - Compass Therapeutics Inc Stock Price and Quote

Finviz176d ago

CMPX Forecast — Price Target — Prediction for 2027

TradingView147d ago

Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity (NASDAQ:CMPX)

Seeking Alpha57d ago

FAQs About CMPX Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for CMPX.

Based on SEC Form 4 disclosures, the Insider Confidence Score for CMPX is currently 60/100, which reflects a moderate accumulation bias. This calculation accounts for a total of 8 purchases and 2 sales by company executives over the last 90 days.

The CEO Conviction Index for CMPX is rated as "High Conviction Accumulation". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.